DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Triple-negative breast cancer (TNBC) is aggressive and lacks standard treatment targets, often leading to resistance and metastasis.
• Current chemotherapy for TNBC has limitations due to frequent development of drug resistance.
• DNA methylation plays a critical role in tumor immune evasion by silencing genes that regulate immune responses.

Purpose of the Study:

• To review the role of DNA methylation in TNBC progression and immune evasion.
• To discuss the potential of combining DNA methylation inhibitors with immune checkpoint inhibitors (ICIs) for TNBC treatment.
• To explore mechanisms, evidence, challenges, and future directions for these combination therapies.

Main Methods:

• Literature review of preclinical and clinical studies on DNA methylation inhibitors and ICIs in TNBC.
• Analysis of the epigenetic mechanisms underlying immune evasion in TNBC.
• Discussion of therapeutic synergies, challenges (heterogeneity, resistance, toxicity), and personalized treatment strategies.

Main Results:

• DNA methylation inhibitors can reverse epigenetic silencing of immune-regulatory genes, enhancing tumor visibility to the immune system.
• Combination therapy with DNA methylation inhibitors and ICIs demonstrates synergistic effects in preclinical models and early clinical investigations.
• Tumor heterogeneity and drug resistance remain significant challenges that require further investigation.

Conclusions:

• Combining epigenetic therapy with DNA methylation inhibitors and immunotherapy with ICIs is a promising strategy for improving outcomes in TNBC.
• Personalized treatment approaches utilizing multi-omics data may optimize the efficacy of these combination therapies.
• Further research is needed to overcome resistance mechanisms and manage toxicity for successful clinical translation.